GlassScriptPhysician profile
Suresh R Nayak
NPI 1871554147
$8,357.68
in general payments reported to CMS, 2019-2025
21 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,288 · 2020: $2,333 · 2021: $495 · 2022: $761 · 2023: $252 · 2024: $502 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,634 · Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,634.43 |
| Food and Beverage | $846.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $6,293.15 | 2019-2025 | Mako |
| Abbvie INC. | $726.76 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $289.17 | 2022-2025 | |
| Therapeuticsmd, INC. | $200.02 | 2019-2021 | |
| Pfizer INC. | $125.49 | 2021-2025 | |
| Myovant Sciences INC. | $114.85 | 2021-2022 | |
| Davol INC. | $103.63 | 2019 | |
| Bard Access Systems, INC. | $99.31 | 2019 | |
| Coopersurgical, INC. | $85.45 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Biogen, INC. | $52.92 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $44.10 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $41.71 | 2019-2021 | |
| Organon LLC | $27.09 | 2021-2022 | |
| Roche Diagnostics Corporation | $26.75 | 2019-2020 | |
| Millicent US INC | $24.76 | 2025 | Femlyv |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $20.77 | 2025 | Acessa Provu System |
| Exact Sciences Corporation | $19.24 | 2023 | Cologuard Collection Kit |
| Lupin INC. | $19.20 | 2019 | |
| Avion Pharmaceuticals | $15.95 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.16 | 2021 | |
| Exeltis, USA INC. | $13.20 | 2023 | Nuvessa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Nayak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.